Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
120M
-
Shares change
-
+761K
-
Total reported value, excl. options
-
$542M
-
Value change
-
+$1.05M
-
Put/Call ratio
-
1.72
-
Number of buys
-
70
-
Number of sells
-
-55
-
Price
-
$4.53
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q1 2024
176 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q1 2024.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 120M shares
of 293M outstanding shares and own 40.93% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (27.5M shares), BAILLIE GIFFORD & CO (23.2M shares), Voya Investment Management LLC (10.6M shares), Capital World Investors (8.35M shares), CREDIT SUISSE AG/ (4.55M shares), ORBIMED ADVISORS LLC (4.18M shares), ArrowMark Colorado Holdings LLC (4.11M shares), BlackRock Inc. (3.9M shares), Founders Fund VII Management, LLC (3.77M shares), and FEDERATED HERMES, INC. (2.82M shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.